	US 12,083,187 B2
	Method of treatment for solid tumors containing hypoxia and/or stroma features
Samaresh Sau, Detroit, MI (US); Arun K. Iyer, Troy, MI (US); and Hashem Alsaab, Dearborn, MI (US)
Assigned to WAYNE STATE UNIVERSITY, Detroit, MI (US)
Appl. No. 16/958,636
Filed by Wayne State University, Detroit, MI (US)
PCT Filed Dec. 28, 2018, PCT No. PCT/US2018/068019 § 371(c)(1), (2) Date Jun. 26, 2020, PCT Pub. No. WO2019/133914, PCT Pub. Date Jul. 4, 2019.
Claims priority of provisional application 62/612,122, filed on Dec. 29, 2017.
Prior Publication US 2020/0338211 A1, Oct. 29, 2020
Int. Cl. A61K 47/69 (2017.01); A61K 47/55 (2017.01); A61K 49/00 (2006.01); A61P 35/00 (2006.01)

CPC A61K 47/6935 (2017.08) [A61K 47/551 (2017.08); A61K 47/6911 (2017.08); A61K 49/0045 (2013.01); A61K 49/0052 (2013.01); A61K 49/0084 (2013.01); A61K 49/0093 (2013.01); A61P 35/00 (2018.01)]

10 Claims

1. A rod-shaped encapsulated nanoparticle, oligomicelle, or nanomicelle comprising:

CARP-1 functional mimetic (CFM) 4.16 (CFM-4.16);

a carbonic anhydrase-IX (CAIX) targeting ligand;

a folate receptor targeting ligand; and

one or more polymer(s) selected from the group consisting of: DBCO-conjugated vitamin E TPSG, SMA-TPGS, 2-hydroxypropyl-β-cyclodextrin (HP-β-CD), sulfobutylether-β-cyclodextrin (SBE-β-CD), phosphatidylethanolamine (PC), ceramide, poloxamer 407, and PLA-PEG.